Intervention description {11a}
TB
After assessing the eligibility of the participants at screening, the study will recruit into five different treatment arms. The experimental and control treatment will be administered daily for 16 weeks. Figure Study design and five different treatment arms. DZD, delpazolid; BDM, bedaquiline, delamanid, moxifloxacin; QD, once daily; BID, twice daily; SCC, sustained culture conversion to negative; WK08, treatment week 08; HR, isoniazid – rifampicin; NTP, national TB programme
